Macrogenics (MGNX) Research & Development (2012 - 2026)

Macrogenics (MGNX) has 15 years of Research & Development data on file, last reported at $35.0 million in Q1 2026.

• Research & Development for Q1 2026 came in at $35.0 million, down 11.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.4 million (down 16.63% YoY), and the FY2025 annual result was $147.2 million, down 16.94% from the prior year.
• Research & Development grew to $35.0 million in Q1 2026 per MGNX's latest filing, from $34.0 million in the prior quarter.
• Over five years, Research & Development peaked at $61.4 million in Q1 2022 and troughed at $30.1 million in Q3 2023.
• A 5-year average of $43.1 million and a median of $43.2 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 37.48% in 2023, then jumped 34.56% in 2024.
• A 5-year view of Research & Development shows it stood at $45.7 million in 2022, then advanced by 3.72% to $47.4 million in 2023, then slipped by 17.87% to $38.9 million in 2024, then decreased by 12.64% to $34.0 million in 2025, then advanced by 2.94% to $35.0 million in 2026.
• Business Quant data shows MGNX's Research & Development at $35.0 million in Q1 2026, $34.0 million in Q4 2025, and $32.7 million in Q3 2025.